Intrauterine instillation of diluted seminal plasma at oocyte pick-up does not increase the IVF pregnancy rate: a double-blind, placebo controlled, randomized study. by von Wolff, Michael et al.
ORIGINAL ARTICLE Infertility
Intrauterine instillation of diluted
seminal plasma at oocyte pick-up does
not increase the IVF pregnancy rate:
a double-blind, placebo controlled,
randomized study
M. vonWolff1,*, S. Ro¨sner2, A. Germeyer2, J. Jauckus2, G. Griesinger3,
and T. Strowitzki2
1Department of Gynaecological Endocrinology, University Women’s Hospital, and Reproductive Medicine, University of Berne, Efﬁngerstrasse
102, Berne 3010, Switzerland 2Department of Gynaecological Endocrinology and Reproductive Medicine, University Women’s Hospital,
University of Heidelberg, Vossstrasse 9, Heidelberg 69115, Germany 3Department of Gynecological Endocrinology and ReproductiveMedicine,
University Hospital of Schleswig-Holstein, Campus Luebeck, Ratzeburger Allee 160, Luebeck 23538, Germany
*Correspondence address. Tel: +41-31-632-1303; Fax: +41-31-632-1305; E-mail: michael.vonwolff@insel.ch
Submitted on April 8, 2013; resubmitted on July 30, 2013; accepted on August 8, 2013
studyquestion: Does intrauterine application of diluted seminal plasma (SP) at the time of ovum pick-up improve the pregnancy rate by
≥14% in IVF treatment?
summaryanswer: Intrauterine instillation of diluted SP at the time of ovum pick-up is unlikely to increase the pregnancy rate by ≥14% in IVF.
what is known already: SP modulates endometrial function, and sexual intercourse around the time of embryo transfer has been sug-
gestedto increase the likelihoodofpregnancy.Apreviousrandomizeddouble-blindpilot studydemonstratedastrongtrendtowards increasedpregnancy
rates following the intracervical application of undiluted SP. As this study was not conclusive and as the ﬁnding could have been confounded by sexual
intercourse, the intrauterine application of diluted SP was investigated in the present trial.
study design, size, duration: A single-centre, prospective, double-blind, placebo-controlled, randomized, superiority trial on women
undergoing IVF was conducted from April 2007 until February 2012 at the University Department of Gynaecological Endocrinology and Reproductive
Medicine, Heidelberg, Germany.
participants/materials, setting, methods: Thestudywaspoweredtodetectan14%increase in theclinicalpregnancyrateand
two sequential tests were planned using the Pocock spending function. At the ﬁrst interim analysis, 279 women had been randomly assigned to intra-
uterine diluted SP (20% SP in saline from the patients’ partner) (n¼ 138) or placebo (n¼ 141) at the time of ovum pick-up.
main results and the role of chance: The clinical pregnancy rate per randomizedpatientwas 37/138 (26.8%) in the SP group and
41/141 (29.1%) in the placebo group (difference:22.3%, 95%conﬁdence interval of the difference:212.7 to+8.2%; P¼ 0.69). The live birth rate per
randomized patient was 28/138 (20.3%) in the SP group and 33/141 (23.4%) in the placebo group (difference:23.1%, 95% conﬁdence interval of the
difference: 212.7 to +6.6%; P¼ 0.56). It was decided to terminate the trial due to futility at the ﬁrst interim analysis, at a conditional power of 62%.
limitations, reasons for caution: The conﬁdence interval of the difference remainswide, thus clinically relevant differences cannot
reliably be excluded based on this single study.
wider implications of the findings: The results of this study cast doubt on the validity of the concept that SP increases endometrial
receptivity and thus implantation in humans.
study funding/competing interest(s): Funding was provided by the department’s own research facilities.
trial registration number: DRKS00004615.
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Introduction
Besides the quality of the embryo, endometrial receptivity plays an im-
portant role in the establishment of pregnancy. Endometrial functional
disorders are likely of little relevance in a physiological context, e.g. spon-
taneous conception in a natural cycle.However, under non-physiological
conditions such as high-dose gonadotrophin stimulation and absence of
sexual intercourse, as it is typically the case in IVF treatment, endometrial
dysfunction is likely to play a role in the non-achievement of pregnancy
despite the transfer of vital embryos. Horcajades et al. (2005) were
able to detect a dysregulation of endometrial gene expression under
high-dose gonadotrophin stimulation. Furthermore, Gutsche et al.
(2003) and von Wolff et al. (2007) demonstrated that seminal plasma
(SP) has a direct effect on endometrial cytokine expression.
In order to improve endometrial receptivity under IVF treatment,
numerous treatments have been proposed, such as the administration
of acetylsalicylic acid and/or heparin, as well as active and passive
immunotherapy. The efﬁcacy of these treatments, however, has never
been unequivocally proved.
Increasing knowledge regarding the high immunomodulatory poten-
tial of SP on endometrial function has motivated various study groups
to use SP as a physiological endometrial stimulant. Tremellen et al.
(2000) showed that the proportion of transferred embryos that were
viable at 6–8 weeks was signiﬁcantly higher in women exposed to
semen through intercourse compared with those who abstained. Von
Wolff et al. (2009) carried out a prospective randomized double-blind
study,whereSPwasapplied intracervically at the timeof follicle puncture.
This pilot study showed that there was a higher clinical pregnancy rate in
the patients treatedwith SP comparedwith thosewho received isotonic
sodium chloride as placebo, although the difference was not statistically
signiﬁcant. The pregnancy rate per embryo transfer was 12% higher
in the SP group than in the placebo group and the pregnancy rate
per randomized patient was 8% higher than in the placebo group.
Another recently published paper supported the result of this study.
Chicea et al. (2013) performed an almost identical study but without
the use of sodium chloride as placebo. They found a non-signiﬁcantly
higher pregnancy rate in 346 treated patients in the SP group than in
the group without SP (55.5 versus 44.0%, P ¼ 0.09) and a signiﬁcant
higher implantation rate (34.7 versus 27.5%, P ¼ 0.026).
Despite inconclusive results, the study from vonWolff et al. gave a ﬁrst
estimate of potential treatment effect sizes on which subsequent study
designs can be based. Accordingly, the present study was designed as
a superiority study, employing a similarmethodological rigour, e.g. a pro-
spective, randomized, placebo-controlled, double-blind, single-centre
study design. In contrast to the pilot study (von Wolff et al., 2009), SP
was instilled into the lower part of the uterine cavity at the time of follicle
aspiration. It was hypothesized that intrauterine instillationwould poten-
tially increase the effect when compared with intra-cervical instillation.
Furthermore, the risk of protocol violation by patients ignoring the
advice not to engage in intercourse required a protocol, which was
less dependent on such effects, especially as absence from intercourse
can hardly be proved (Gallo et al., 2006).
As the intrauterine instillation of undiluted SP can cause uterine con-
tractions, SP was used in a diluted form in the present trial. The in vitro
studiesmentioned above have not investigatedwhether the endometrial
effects can also be achieved by using diluted SP.
Materials andMethods
This is a single-centre, two-armed, randomized, placebo-controlled, double-
blind clinical study investigating superiority of SP administration at the time of
oocyte pick-up in a German university afﬁliated IVF programme.
Subjects
All couples undergoing IVF or ICSI treatment at the Department of Gynae-
cology and Reproductive Medicine, Heidelberg, between April 2007 and
February 2012 were considered for enrolment in the trial. Of these, 279
women (25.2–43.5 years of age) were eligible for enrolment and consented
to participate in the study. Participation was limited to one treatment cycle
per couple. The exclusion criteria included the presence of hepatitis B, C
or human immunodeﬁciency virus, leukocytospermia or other signs of infec-
tion andmenwith,300 ml of SP.The studywas approvedby the local ethical
committee and each patient’s approval was given by written consent.
Clinical IVF protocol
Either a long agonist (n ¼ 267), short agonist (n ¼ 2) or antagonist (n ¼ 10)
protocol was applied for ovarian stimulation.
For the long agonist protocol, pituitary desensitization was performed
by intranasal application of the GnRH agonist 0.4 mg nafarelin acetate
(Synarelaw, Merck Serono, Darmstadt, Germany), starting in the luteal
phase of the previous cycle. After down-regulation of the pituitary gland,
patients received in addition either 150–300 IU of recombinant FSH
(Gonal Fw, Merck Serono) or highly puriﬁed HMG (Menogon HPw,
Ferring, Hamburg, Germany) per day. Dosages were adjusted according to
estradiol concentrations and vaginal ultrasound scan.
For the short agonist protocol, nasal application of 0.4 mgnafarelin acetate
was startedonDay1or 2 of themenstrual cycle andwas continued until ovu-
lation induction. FSH or HMG stimulation was started on Day 3 of the cycle
using the dosages as described above.
For the antagonist protocol, FSH or HMG was initiated between Days 3
and 5 of the menstrual cycle using the dosages as described above. GnRH
antagonists (Orgalutranw, MSD, Haar, Germany or Cetrotiodew, Merck
Serono) were started between Days 6 and 7 of the menstrual cycle and con-
tinued until ovulation induction.
Once an adequate ovarian response had been conﬁrmed, FSH and HMG
were discontinued and 10 000 IU of urinary hCG (Predalonw, MSD, Haar,
Germany) or 250 mg of recombinant hCG (Ovitrellew, Merck Serono) was
administered to induce ovulation. Transvaginal oocyte retrieval was sched-
uled 34–36 h after hCG administration and was performed under general
anaesthesia. Fertilization was achieved by standard IVF or ICSI. One to
three oocytes at the pronuclear stage were selected and cultured for
another 1– 2 days, when they were transferred back into the uterus. Selec-
tion of embryos for transfer was not performed due to the restrictions of the
German embryo protection law. Intravaginal progesterone (600 mg/day)
was used as luteal support.
Randomization
Physicians reported a scheduled oocyte pick-up with the information rele-
vant for randomization to the IVF laboratory once the stimulation was
started. The technician (J.J.) in the laboratory randomized the patient 1 day
before the oocyte aspiration was scheduled. The technician took SP or the
placebo to the operating theatre on the day of aspiration. The blinded
sample was handed over to the physician to inject the sample into the
uterine cavity under general anaesthesia.
For randomization, two randomization lists (Stratums I and II) with block
randomization for every 20 patients were prepared before the onset of the
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study. Patients were consecutively added to the list on the day that follicle as-
piration was scheduled. Accordingly patients were allocated to one of the
treatment arms.
Stratums I and II were introduced as the pregnancy rate of IVF/ICSI
treatments is highly dependent on the age of the patient and on the
number of previous treatment cycles. Stratum I (expected low pregnancy
rate) was deﬁned as: ≥36 or ,36 years of age and transfer of ≥6
embryos in ≥3 embryo transfers without a pregnancy in previously per-
formed IVF/ICSI cycles. All other patients were allocated to Stratum II
(expected a high pregnancy rate).
Preparation and application of SP
Semen sampleswereobtained≥1/2 weeksbefore follicle aspirationbymas-
turbation from the patient’s partner and were collected in sterile ﬂasks.
SP was extracted by centrifugation of ejaculates at 600 g for 15 min.
A second round of centrifugation was performed at 10 000 g for 15 min to
extract all spermatozoa. SP was analysed several times to exclude remaining
contamination with spermatozoa. None of the samples contained any
spermatozoa after centrifugation. Then 400 ml of supernatant were diluted
with 1600 ml of sterile sodium chloride and mixed. From this solution,
1500 ml was stored in 2 ml syringes at 2208C (verum). For the placebo,
1500 ml of sterile sodium chloride was also stored in 2 ml syringes at
2208C. Blinding of the samples was achieved by using a placebo (sodium
chloride), which could not be differentiated from SP due to the same
optical appearance. SP and placebo sampleswere stored in separate freezers
in exactly the samesyringeswith thenamesof bothpartners attached for later
allocation.
On thedayof oocyte collection, blinded SPor placebo sampleswere taken
out of the freezer by the technician around 30–60 min before the aspiration
of the follicles and were transferred to the operating theatre. Follicles were
aspirated and bleeding was stopped. An insemination catheter (Laboratoire
C.C.D., Paris, France) was introduced just above the end of the cervix and
1500 ml SP or placebo was injected.
Outcomemeasures, statistics and sample size
The study was based on the hypothesis of superiority of SP administration in
termsof clinical pregnancy likelihood. Basedonan increase inpregnancy rates
found in the pilot study (vonWolff et al., 2009), it was calculated that group
sample sizes of 269 in the SP group and 269 in the placebo group could
achieve 90% power to detect a difference in clinical pregnancy rate of 14%.
This difference of 14% was considered as clinically meaningful by the
authors. The clinical pregnancy rate in the SP group was assumed to be
24% under the null hypothesis and 38% under the alternative hypothesis.
The clinical pregnancy rate in the placebo group was expected to be 24%.
The test statistic is set at an alpha level of 0.05 using a two-sided Z-test
with continuity correction. These results assume that two sequential tests
are made using the Pocock spending function to determine symmetrical
test boundaries (Software program used for this calculation: PASS 2005,
Kaysville, Utah, USA). Thus, an interim analysis was planned when 50% of
the total sample hadbeen randomized. If that interim analysis revealedaposi-
tive effect of SP administration at an alpha of 0.031, the study had to be pre-
maturely stopped at a power of 60% and superiority had been proved. If this
was not the case, the study had to be continued.
The primary outcome measure is the clinical pregnancy rate (fetal heart
beat) per randomized patients 4–5 weeks after follicle aspiration. The SP
andplacebogroups aredescribed in termsof age, etiologyof infertility, stimu-
lation protocol, proportion of patients undergoing IVF or ICSI, average
number of transferred embryos and average number of blastomeres per
transferred embryo. All data are presented descriptively as means (+
standard deviation or ranges), or proportions with 95% conﬁdence intervals,
as appropriate. Fisher’s exact test was used to compare dichotomous
characteristics of the SP and placebo groups, as well as pregnancy rates in
both groups. The signiﬁcance level alpha was set to 5%.
Results
A pre-planned interim analysis was performed at 50% recruitment, e.g.
when 279 patients had been enrolled and randomized. The clinical preg-
nancy rate per randomized patient was 37/138 (26.8%) in the SP group
and 41/141 (29.1%) in the placebo group (difference:22.3, 95% conﬁ-
dence interval of the difference: 212.7 to +8.2%; P ¼ 0.69). The live
birth rate per randomized patient was 28/138 (20.3%) in the SP group
and 33/141 (23.4%) in the placebo group (difference:23.1, 95% conﬁ-
dence interval of the difference: 212.7 to +6.6%; P ¼ 0.56).
Contrary to thehypothesis and thepilot study, no trend towardaposi-
tive treatment effect was seen with SP administration. The z-score value
of 20.2858 was exceeding the lower boundary of 22.1570 as deter-
mined by the Pocock spending function for the interim analysis. At a con-
ditional powerof 62%, it thuswasdecided to terminate the trial due to its
futility. If the comparator pregnancy rate had remained stable at 29% till
the end of the trial (e.g. when the pre-planned sample size had been
reached), a pregnancy rate of 59.7% would have been necessary to
reach statistical signiﬁcance in the remaining 130 patients to be allocated
to the intervention.
Table I describes the demographics and outcomes of the two groups.
Characteristics of the 279 trial participants were similar and not statistic-
ally different in the SP and placebo groups. Therewere 143 patients allo-
cated to Stratum I and 136 patients allocated to Stratum II. In 239
patients, embryos were transferred. Of those, 122 patients received
SP and 117 placebo. Even though diluted SP was injected into the
uterine cavity, neither painful cramps nor infections were reported at
oocyte pick-up or 2 weeks later (Fig. 1).
An 8% lower pregnancy rate in Stratum I (pregnancies: 34/143 ¼
23.8%), including patients ≥36 years or those with previous implant-
ation failure, than in Stratum II (pregnancies: 44/136 ¼ 32.4%), con-
ﬁrmed the adequacy of stratiﬁcation. Adequacy of randomization was
conﬁrmed by the similar characteristics of trial participants in the two
trial arms (Table I).
Discussion
The study revealed that intrauterine applicationof SPat the timeof follicle
aspiration in 279 IVF treatment cycles did not increase thepregnancy rate
comparedwith placebo. It is important to emphasize that at theoutset of
this study some over-enthusiasm about a supposed effect of SP on im-
plantation likelihood led to the decision to design a superiority trial,
which could be prematurely terminated in favour of the alternative hy-
pothesis using a common alpha spending function approach to group se-
quential testing. It is also important to emphasize that no distinct lower
boundary of the alpha spending function to determine futility was pre-
speciﬁed. With the results at the ﬁrst interim analysis in hand, it was
then decided, on both clinical and statistical reasoning, to terminate
the study early. There are, however, important drawbacks to this deci-
sion: ﬁrst, there is still a chance, albeit very small, that SP instillation
would be superior to placebo had the trial been continued. Secondly,
the true effect of SP instillation into the uterine cavity could well be nega-
tive andwith the limited sample size such a phenomenon cannot be ruled
out with conﬁdence.
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The potential effect of ejaculate or SP on endometrial function has
been the subject of numerous investigations for several years, mainly in
animal models. However, when interpreting these studies, it should be
remembered that in many species such as mouse, horse and pig, the
ejaculate reaches the uterine cavity physiologically, whereas probably
only very small amounts ascend through the cervical canal in the
human system.
In the animal model it has been shown that SP or sperm in the cervix
and endometrium induce the synthesis of proinﬂammatory cytokines
(Robertson, 2007). The cytokines and the paternal antigens such as
sperm and seminal leukocytes recruit and activate inﬂammatory cells in
the endometrium, including macrophages, dendritic cells and granulo-
cytes. Furthermore, paternal antigens have been suggested to trigger a
beneﬁcial tolerant immune response towards paternal antigens that
then favours the successful implantation of the resultant embryo
sharing those same paternal antigens (Robertson et al., 2013). Even
though SP has signiﬁcant molecular and cellular effects on the endomet-
rium in animals, SP does not appear to be essential for the establishment
of a pregnancy in these animals. Tests have shown that intrauterine in-
semination, even after extraction of SP, leads to pregnancy in horses
and pigs (Katila, 2012).
In humans, investigations have been largely limited to in vitro experi-
ments. Gutsche et al. demonstrated that SP stimulates the expression
of leukaemia inhibitory factor (LIF) and interleukin 6 (IL-6) in vitro
(Gutsche et al., 2003). Furthermore, a recent study demonstrated that
SP increases the decidualization of stromal cells (Doyle et al., 2012).
The concept of this study implies that active SP factors reach the endo-
metrial stromal cells through the luminal epithelium. Based on investiga-
tions by Kucharski et al. (2008), who detected a transfer of cytokines
administered into the uterine cavity into the bloodstream of pigs, such
a mechanism is conceivable. The above study also implies that acceler-
ated decidualization leads to an improvement in the endometrial im-
plantation efﬁciency. However, recent studies have shown, by using
antagonist protocols, that an early rise in progesterone and the probable
resulting decidualization leads to a reducedpregnancy rate (Ochsenku¨hn
et al., 2012).
Because studies on animal models and in vitro studies can only
be applied to the clinical situation to a limited extent, only clinical
studies can ultimately clarify whether SP has a relevant effect on preg-
nancy rates.
On the basis of this, the present study was carried out in succession of
a study published in 2009 (vonWolff et al., 2009). The trend of the pre-
vious study which showed a positive effect of SP could not be conﬁrmed
in this study.
There are several possible reasons for the diverging results of
these studies.
.............................................................................................................................................................................................
Table I Characteristics of trial participants and outcome of treatment assignment
SP (n5 138) Placebo (n5 141) Difference (95% CI) P
Mean age (years) 34.6 (25.2–43.5) 34.9 (25.2–41.3)
Etiology of infertility (n/total)
Male factor 49/138 50/141
Tubal factor 19/138 15/141
Idiopathic 5/138 10/141
Others 8/138 7/141
Unknown 57/138 59/141
Long agonist protocol 134/138 133/141
Short agonist protocol 0 2/141
Antagonist protocol 4/138 6/141
Patients with previous implantation failurea (n/total) 70/138 (Stratum I) 72/141 (Stratum I)
IVF (n/total) 56/138 65/141
ICSI (n/total) 82/138 76/141
Median no. of transferred embryos 1.83 (1–3) 1.86 (1–3)
No. of blastomeres/transferred embryo 3.8 3.8
Clinical pregnancy rate: Stratum I (n/total)b 15/70 (21.4%) 19/73 (26.0%) 24.6% (218.3 to 9.4) 0.56
Clinical pregnancy rate: Stratum II (n/total)b 22/68 (32.4%) 22/68 (32.4%) 0% (215.4 to 15.4) 1.00
Total clinical pregnancies (n/total) 37/138 (26.8%) 41/141 (29.1%) 22.3% (212.7 to 8.2) 0.69
Abortions (n/total) 8/138 (5.8%) 6/141 (4.3.%) 1.5% (24.9 to 7.2) 0.59
Tubal pregnancies (n/total) 1/138 (0.7%) 1/141 (0.7%) 0% (23.2 to 3.3) 1.00
Deliveries (n/total) 28/138 (20.3%) 33/141 (23.4)c 23.1 (212.7 to 6.6)c 0.56
aPrevious implantation failure: transfer of ≥6 embryos in ≥3 embryo transfers without a pregnancy.
bStratum I: expected low pregnancy rate: ≥36 or ,36 years of age and transfer of ≥6 embryos in ≥3 embryo transfers without a pregnancy in previously performed IVF/ICSI-cycles.
Stratum II: expected high pregnancy rate: all other patients.
cInformation about whether live birth occurred is missing for one patient with a clinical pregnancy in the placebo group. This pregnancy was not counted as a live birth. If this pregnancy
resulted in live birth, the placebo group live birth rate is 34/141 (24.1%) and the difference between treatments is 23.8% (95% CI: 213.5 to 6.0; P ¼ 0.47).
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Firstly, the treatment concepts are different. In the study published in
2009, pure SP was instilled into the cervix, which is very close to the
physiological situation during sexual intercourse. In our new study in
which SP was injected into the uterine cavity, a treatment concept was
chosen which is largely independent, but which represents an non-
physiological form of treatment. Indeed, SP has never been proved to
ascend in substantial volumes through the cervix into the uterine
cavity. In humans, endometrial inﬂammatory responses induced by SP
have only been shown in vitro (Gutsche et al., 2003), whereas cervical in-
ﬂammatory responses following exposure to ejaculate have been
demonstrated in vivo (Sharkey et al., 20012a). In addition, in vitro experi-
ments have revealed that this effect is at least in part due to SPandnot just
due to semen (Sharkey et al., 2012b). However, even though the intra-
cervical and intrauterine treatment approach seems to be very different,
in practice, they are possibly not. During the cervical instillation of SP, as
performed in the ﬁrst study, a substantial amount of SP probably also
enters the uterine cavity. It can therefore be speculated that in both
studies the effect of undiluted intracervical SP and diluted intrauterine
SP would exert the same effect on the uterine endometrium. As the
effect on the cervix and the vaginawas howevermuchmorepronounced
in the ﬁrst studyand in the studybyChicea et al. (2013), this suggests, that
in humans SP does act but more via the cervix and vagina than via the
uterine cavity.
Furthermore, it could be speculated that the passage of the transfer
catheter through the cervix already would have a positive effect,
through which the positive effect of the SP was overshadowed. Meta-
analyses have shown that a hysteroscopy, even without proof of any
pathophysiological results, signiﬁcantly increases the pregnancy rate of
a subsequent IVF treatment (El-Toukhy et al., 2008). In addition,
several studies have demonstrated an increased pregnancy rate after
endometrial injury before IVF treatment (Nastri et al., 2012). This
effect was not seen after endometrial injury at the time of follicle punc-
ture. However, as the introduction of a transfer catheter possibly also
causes some cervical trauma, it might be speculated that this would
have a positive effect in our new study, although in reality such an
effect was not observed.
Finally, there is the possibility that intracavitary treatmentwith SP does
not have any clinically relevant immunomodulatory effects on the endo-
metrium at all or that the dilution of SP reduced the effect to such an
extent that it was not pronounced enough to have a substantial effect
on endometrial function.
Indeed, the present study suggests that SP instillation into the uterine
cavity is unlikely to increase the chance of clinical pregnancy, at least not
by a rate ≥14% as initially hypothesized.
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